Assessment of disease activity control and evaluation strategy in patients with Takayasu arteritis undergoing cardiac surgery: a retrospective cohort study
By
XinPei Liu
Di Wu
Jun Zheng
ChaoJi Zhang
ShangDong Xu
XingRong Liu
GuoTao Ma
Sheng Yang
JianZhou Liu
Qi Miao
June 3, 2026
Clinical Scorecard: Evaluation of Disease Activity Management and Assessment Approaches in Takayasu Arteritis Patients Undergoing Cardiac Surgery: A Retrospective Cohort Analysis
At a Glance
Category Detail
Condition Key Mechanisms Large-vessel vasculitis affecting the aorta and major branches. Target Population Care Setting Single-center, multidisciplinary approach in a cardiac surgery context.
Key Highlights
Higher incidence of surgical site complications in TAK patients (17.19%) compared to controls (0%). No significant difference in early postoperative mortality/complications between TAK and non-TAK patients. TAK patients had a significantly higher risk of cardiovascular re-hospitalization and new cardiovascular surgery. Initial surgical failure risk was not significantly different between TAK and non-TAK cohorts. Guideline-Based Recommendations
Diagnosis
Patients must meet the 1990 American College of Rheumatology diagnostic criteria for TAK. Management
Implement a multidisciplinary approach for preoperative disease activity control and assessment. Monitoring & Follow-up
Conduct repeated clinical and biomarker assessments preoperatively. Risks
Patients with TAK have an augmented risk of perioperative and postoperative complications. Patient & Prescribing Data
64 patients with Takayasu's arteritis undergoing cardiac surgery.
Preoperative protocol includes corticosteroids and potential escalation to csDMARDs.
Clinical Best Practices
Utilize a structured, stepwise preoperative pharmacological protocol. Ensure standardized disease activity assessment criteria are in place. Related Resources & Content
